Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: A meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 1, 2015, Pages 206-212

  Qiu, Mantang ^a,b   Wang, Jie ^a   Xu, Youtao ^a,b   Ding, Xiangxiang ^a,b   Li, Ming ^a   Jiang, Feng ^a   Xu, Lin ^a   Yin, Rong ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING TUMOR DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CIRCULATING TUMOR CELL; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENE MUTATION; GOLD STANDARD; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PROTO ONCOGENE; TUMOR EMBOLISM;

CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASTIC CELLS, CIRCULATING;

EID: 84921032852     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0895     Document Type: Article

References (55)

1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
2. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
3. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al.Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42.
4. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
5. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006;116:2695-706.
6. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, et al. Influence of chemotherapy on EGFR mutation status among patients with nonsmall-cell lung cancer. J Clin Oncol 2012;30:3077-83.
7. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
8. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol 2013;31:17-22.
9. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
10. Spellman PT, Gray JW. Detecting cancer by monitoring circulating tumor DNA. Nat Med 2014;20:474-5.
11. De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013;10:377-89.
12. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
13. ctDNA is a specific and sensitive biomarker in multiple human cancers. Cancer Discov 2014;4:OF8.
14. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
15. Zhou J, Shi YH, Fan J. Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma. Semin Oncol 2012;39:440-8.
16. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.
17. Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L, et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat Rev 2014;40:648-55.
18. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
19. Wang S, Han X, Hu X, Wang X, Zhao L, Tang L, et al. Clinical significance of pretreatment plasma biomarkers in advanced non-small. Clin Chim Acta 2014;430C:63-70.
20. Jing CW, Wang Z, Cao HX, Ma R, Wu JZ. High resolution melting analysis for epidermal growth factor receptor mutations. Asian Pac J Cancer Prev 2013;14:6619-23.
21. Zhang H, Liu D, Li S, Zheng Y, Yang X, Li X, et al. Comparison of EGFR signaling pathway somatic DNA mutations derived from. J Mol Diagn 2013;15:819-26.
22. Brevet M, Johnson ML, Azzoli CG, Ladanyi M. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass. Lung Cancer 2011;73:96-102.
23. Huang Z, Wang Z, Bai H, Wu M, An T, Zhao J, et al. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Cancer 2012;3:334-40.
24. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009;27:2653-9.
25. Bai H, Zhao J, Wang SH, An TT, Wang X, Wu MN, et al. The detection by denaturing high performance liquid chromatography of epidermal growth factor receptormutation in tissue and peripheral blood from patients with advanced non-small cell lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 2008;31:891-6.
26. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
27. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The evidence-based medicine working group. JAMA 1994;271:703-7.
28. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003;29:1043-51.
29. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-93.
30. Dwamena BA. midas: computational and graphical routines for metaanalytical integration of diagnostic accuracy studies in Stata. Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, Michigan; 2007.
31. Kim HR, Lee SY, Hyun DS, Lee MK, Lee HK, Choi CM, et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res 2013;32:50.
32. Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour. J Clin Pathol 2013;66:1065-9.
33. Lv C, Ma Y, Feng Q, Fang F, Bai H, Zhao B, et al. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma. World J Surg Oncol 2013;11:96.
34. Kim ST, Sung JS, Jo UH, Park KH, Shin SW, Kim YH. Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? Med Oncol 2013;30: 328.
35. Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L, et al. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther 2012;5:439-47.
36. Hu C, Liu X, Chen Y, Sun X, Gong Y, Geng M, et al. Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep 2012;28:1815-21.
37. Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Kobayashi N, et al. Application of a highly sensitive detection system for epidermal growth factor. J Thorac Oncol 2012;7:1369-81.
38. Zhao X, Han RB, Zhao J, Wang J, Yang F, ZhongW, et al. Comparison of epidermal growth factor receptormutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013;85: 119-25.
39. Yam I, Lam DC, Chan K, Chung-ManHo J, Ip M, Lam WK, et al. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung. J Thorac Oncol 2012;7:1131-40.
40. Jiang B, Liu F, Yang L, Zhang W, Yuan H, Wang J, et al. Serum detection of epidermal growth factor receptor gene mutations using. J Int Med Res 2011;39:1392-401.
41. Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from. Clin Cancer Res 2011;17:7808-15.
42. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012;7:115-21.
43. Sriram KB, Tan ME, Savarimuthu SM, Wright CM, Relan V, Stockwell RE, et al. Screening for activating EGFR mutations in surgically resected nonsmall cell lung. Eur Respir J 2011;38:903-10.
44. Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small. Clin Cancer Res 2009;15:2630-6.
45. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma. Clin Cancer Res 2009;15:2076-84.
46. He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, et al. Detection of epidermal growth factor receptor mutations in plasma by mutantenriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 2009;125: 2393-9.
47. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor. Clin Cancer Res 2006;12:3915-21.
48. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007;97:778-84.
49. Li X, Ren R, Ren S, Chen X, Cai W, Zhou F, et al. Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients. Transl Oncol 2014;7:341-8.
50. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumorDNAas a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
51. Weber B, Meldgaard P, Hager H, Wu L, Wei W, Tsai J, et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer 2014;14:294.
52. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285-93.
53. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129-35.
54. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90.
55. Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW. BEA Ming up for detection and quantification of rare sequence variants. Nat Methods 2006;3:95-7.